The pharmacology of selegiline ((−)deprenyl). New aspects
- 1 November 1989
- journal article
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 80, 83-91
- https://doi.org/10.1111/j.1600-0404.1989.tb01787.x
Abstract
– Male rats were treated from the end of their 2nd year of life either with saline (1 ml/kg, s.c.) (n=66) or with deprenyl (0,25 mg/kg, s.c.) (n=66) three times a week until death. Whereas none of the two-year-old saline-treated rats displayed full scale sexual activity, this appeared in 64 out of 66 rats on deprenyl. The longest living rat in the saline-treated group lived 164 weeks. The average lifespan of the group was 147.05±0.56 weeks. The shortest living animal in the (−)deprenyl-treated group lived 171 weeks and the longest living rat died during the 226th week of its life. The average lifespan was 191.91±2.31 weeks. This is the first instance that a well-aimed medication prolonged lifespan of members of a species beyond their maximum age of death (182 weeks in the rat). A close relation between sexual activity and lifespan was detected. Male rats (n=94) selected from an 8-month old population as sexually inactive ones were found to be miserable learners. This group was treated either with saline (1 ml/kg, s.c.) (n=46) or with (−)deprenyl (0.25 mg/kg, s.c.) (n=48) three times a week for 36 weeks. Their performance in the shuttle box during 5 consecutive days was tested before and after treatment. The total number of conditioned avoidance responses (CAR) which remained unchanged in the saline-treated group (6.53±1.41 before and 5.98±1.15 after treatment) increased from 5.57±0.65 to 20.73±1.39 (p<0.001) in the (−)deprenyl-treated group of rats. (−)Deprenyl-treatment (0.25-2 mg/kg, s.c., daily for 21 days) increased superoxide dismutase (SOD) activity in the striatum of CFY rats, whereas clorgyline-treatment (0.1–1 mg/kg) inhibited it.Keywords
This publication has 12 references indexed in Scilit:
- The striatal dopamine dependency of life span in male rats. Longevity study with (−)deprenylMechanisms of Ageing and Development, 1988
- L-Deprenyl in Alzheimer's DiseaseArchives of General Psychiatry, 1987
- Role of B-Type Monoamine Oxidase Inhibition in the Treatment of Parkinson’s DiseasePublished by Springer Nature ,1986
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985
- The facilitation of dopaminergic activity in the aged brain by (−)deprenyl. A proposal for a strategy to improve the quality of life in senescenceMechanisms of Ageing and Development, 1985
- Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeysEuropean Journal of Pharmacology, 1984
- Deprenyl (selegiline): the history of its development and pharmacological actionActa Neurologica Scandinavica, 1983
- Long-Lasting, True Aphrodisiac Effect of (-)-Deprenyl in Sexually Sluggish Old Male RatsPublished by S. Karger AG ,1983
- THE TYPE OF MAO IN THE NIGROSTRIATAL DOPAMINERGIC NEURONS OF THE RATPublished by Elsevier ,1979
- The possible mechanisms of action of (-)deprenyl in Parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1978